Article

Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.

Johns Hopkins Oncology Center, Pediatric Oncology, Baltimore, MD 21205.
Blood (Impact Factor: 10.43). 08/1988; 72(1):299-307.
Source: PubMed

ABSTRACT Cell surface phenotypes of 113 B lineage acute lymphocytic leukemia (ALL) cases, defined by the presence of HLA-DR and at least one B-cell-specific antigen (either CD19, CD20, or CD22), were compared with antigen-defined stages of normal B lymphocyte development. The cases were first evaluated for expression of HLA-DR, CD19, CD34, CD10, CD20, and CD22 by indirect one-color immunofluorescence. Pairwise comparisons of cell surface marker expression were performed for each leukemic sample: no correlations were observed for paired antigen expression on the leukemic samples using antigens expressed either early or late during normal B lymphoid development. Complete immunophenotypes of the cases were then compared with normal B-cell developmental stages. Sixteen different complete immunophenotypes were observed on the leukemias that were not found in normal marrow; at least 78% of the cases demonstrated such "asynchronous" combinations of B lymphoid-associated differentiation antigens. Several samples were subsequently studied by two-color immunofluorescence, and the presence of doubly labeled cells with "asynchronous" antigen combinations was confirmed. These results indicate that the majority of B lineage leukemias exhibit "developmental asynchrony," as compared with normal marrow B cells. The data further suggest that ALL cases do not accurately represent cells arrested at the stage where the leukemogenic event occurred. Rather, ALL appears to be a disease in which there may be maturation of leukemic blasts; but this maturation is "asynchronous" when compared with the normal developmental process.

0 Followers
 · 
78 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Analysis of differentiation antigens on leukaemic blasts is routinely done for diagnostic purposes, i.e. determination of stage of differentiation and lineage assignment. Acute lymphoblastic leukaemias are also frequently characterized by a leukaemia-associated immunophenotype (LAIP), either the coexpression of differentiation antigens physiologically restricted to other stages of differentiation (asynchronous LAIP) or cell lineages (aberrant LAIP). We defined LAIP in 241 consecutive unselected B-lineage (n = 193) and T-lineage (n = 48) ALL by three-colour flow cytometry using directly conjugated monoclonal antibodies. The incidence of LAIP was found to be 91.7%. In 63% of patients two to six leukaemia-associated expression patterns were detected. In order to study the specificity of LAIP in a therapy-relevant setting, remission bone marrow samples from patients with B-lineage ALL were analysed for the expression of T-lineage-associated phenotypes on the normal bone marrow cells and vice versa. The frequency of all T-lineage LAIP+ cells and all aberrant B-lineage LAIP+ cells was <1% in regenerating bone marrow samples at different timepoints. The incidence and clinical significance of LAIP+ cells was studied in 196 remission marrows of 70 ALL patients (55 remaining in CCR, 14 with bone marrow relapse, one with isolated CNS relapse). The presence of >1% LAIP+ at two consecutive timepoints predicted 5/8 bone marrow relapses in B-lineage ALL. The occurrence of LAIP+ cells >1% in T-lineage ALL after induction therapy predicted relapse in 7/7 cases. In conclusion, flow cytometric detection of LAIP+ cells appears to be a powerful tool for the prediction of outcome in ALL.
    British Journal of Haematology 03/1999; 105(1):241 - 255. DOI:10.1111/j.1365-2141.1999.01300.x · 4.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical utility of early response measures Approximately 80% of children with acute lymphoblastic leukemia (ALL) are cured with contemporary risk-directed treatment, with therapies of different intensities administered to patient groups with differential risks of relapse. Many different clinical and biological features are used to identify different risk groups. Early response to therapy, defined as the initial degree and rate of disease regression prior to end induction, is one of the most powerful. Simple enumeration of blasts remaining in peripheral blood (PB) or bone marrow (BM) at defined times during induction therapy is highly predictive of treatment outcome among large groups of patients with ALL.(1) The Berlin-Frankfurt-Munster (BFM) group showed in ALL-BFM 83 that the number of blasts remaining in the peripheral blood following seven days treatment with prednisone and a single dose of intrathecal methotrexate separates patients into two subgroups with divergent outcomes.(2) Prednisone good responders (PGR) consist of the approximately 90% of patients that have < 1000 blasts/ml remaining in the PB and have an excellent outcome. In contrast, prednisone poor responders (PPR) that have = 1000 blasts/
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the past 10 years immunophenotyping of ALL has been demonstrated to be useful for selecting and scheduling chemotherapy. Different drug regimens are now used for T-cell and B-cell ALL than for non-T non-B ALL with the result that survival and cure of T-cell and B-cell ALL have been considerably improved. The use of different drug regimens for different immunophenotypic varieties of non-T non-B ALL is being tested. "Prognostic factors" of ALL are artifacts of data analysis and treatment and should no longer be used for guiding treatment. The administration of all-inclusive multiple-drug therapy to all patients with ALL regardless of species should also be abandoned. Minimally effective drugs can interfere with dosage and continuity of more effective drugs, and can result in side effects and sequelae that increase the mortality and morbidity of treatment. Since acute leukemias are genetic disorders of hematopoiesis the future direction of leukemic therapy is toward genetic targeting.
    Haematology and blood transfusion 02/1989; 32:27-36.